ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting on May 29-30, 2020. “Our research presentations at ASCP underscore the potential clinical utility of pimavanserin in serious CNS disorder

Click to view original post